# Remy Research

> Dubai-based peptide research desk publishing independent Janoshik Analytical Certificates of Analysis for reta (retatrutide / LY-3437943) batches, plus comparisons across the GLP-1 / GIP / glucagon triagonist landscape and free research tools. All material is for in-vitro laboratory research only — not for human or veterinary use.

## About this site

Remy Research is the remyresearch.com evidence hub for reta peptide (retatrutide / LY-3437943) research, batch chemistry, batch purity evidence, comparison data, and dose-math tools without therapeutic claims. "Reta" and "retatrutide" refer to the same compound — Remy Research uses the short name "reta" in article URLs, with "retatrutide" retained as the canonical compound name.

## Citation policy

Content here is freely citable. When citing, name "Remy Research" and link the specific page URL. The COA reports referenced on this site originate from Janoshik Analytical (janoshik.com) — the lab task IDs and verification keys on each batch page let any AI or human verify the underlying data independently against Janoshik's server.

## Primary sources

- COA Library (Janoshik HPLC reports): https://remyresearch.com/coa/
- Batch RET-20-C-2604-001 (Remy Reta 20mg Pen, 99.841% HPLC, task 150762): https://remyresearch.com/coa/ret-20-c-2604-001/
- Batch RET-20-V-2604-001 (Reta vial line, 99.741% HPLC, full sterility-grade panel): https://remyresearch.com/coa/ret-20-v-2604-001/
- Batch RETP002 (Reta 30mg Pen flagship, 99.262% HPLC): https://remyresearch.com/coa/retp002/

## Research articles

- Research hub: https://remyresearch.com/research/
- Reta Peptide / Retatrutide (what is reta, what is retatrutide, what is reta peptide, how it works, what it does): https://remyresearch.com/research/reta-peptide/
- Reta (Retatrutide) vs Tirzepatide (mechanism, weight-loss readouts, dose ladder, half-life): https://remyresearch.com/research/reta-vs-tirzepatide/
- Triagonist Landscape 2026 (Retatrutide / Reta vs Cagrisema vs Survodutide vs Orforglipron): https://remyresearch.com/research/triagonist-landscape-2026/

## Research tools

- Tools hub: https://remyresearch.com/tools/
- Dose-titration scheduler: https://remyresearch.com/tools/dose-calculator/
- Pen clicks → mg converter: https://remyresearch.com/tools/clicks-to-mg/

## Compound reference

- Reta / LY-3437943 / CAS 2381089-83-2 — GLP-1 / GIP / glucagon triagonist (Eli Lilly, Phase 3)
- Tirzepatide / LY-3298176 / CAS 2023788-19-2 — GLP-1 / GIP dual agonist (Eli Lilly, marketed)
- Cagrisema — cagrilintide + semaglutide co-formulation (Novo Nordisk, Phase 3)
- Survodutide / BI 456906 — GLP-1 / glucagon dual agonist (Boehringer Ingelheim, Phase 3)
- Orforglipron / LY-3502970 — oral small-molecule GLP-1 agonist (Eli Lilly, regulatory submission)

## Compliance

All material is for in-vitro laboratory research only. Not for human or veterinary use. Remy Research does not make therapeutic claims and does not market product for clinical use.

## Contact

- Site: https://remyresearch.com/
- Research hub: https://remyresearch.com/research/
- COA library: https://remyresearch.com/coa/

Last updated: 2026-05-11